A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor Vlla (Recombinant) in Congenital Hemophilia A or B Patients with Inhibitors to Factor VIII or IX
|Effective start/end date||6/1/14 → 5/31/18|
- REVO BIOLOGICS, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.